Humacyte, Inc. (HUMA) Q3 2023 Earnings Call Transcript


Humacyte, Inc. (NASDAQ:HUMA) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET

Company Participants

Lauren Marek – Investor Relations, LifeSci Advisors

Laura Niklason – President and Chief Executive Officer

Dale Sander – Chief Financial Officer and Chief Corporate Development Officer

Conference Call Participants

Suraj Kalia – Oppenheimer

Bruce Jackson – The Benchmark Company

Operator

Good afternoon, ladies and gentlemen, and welcome to the Humacyte Third Quarter Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded.

I will now turn the call over to Lauren Marek with LifeSci Advisors. Please go ahead.

Lauren Marek

Thank you, operator.

Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this afternoon and in our Form 10-Q, which after filing may be accessed from the Investors page of the Humacyte website.

Joining me on today’s call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Dale Sander, Chief Financial Officer and Chief Corporate Development Officer; and Dr. Heather Prichard, Chief Operating Officer. Dr. Niklason will provide a summary of the company’s progress during



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *